EMA 安全委员会建议在肝损伤风险审查期间，停用乌利司他（Ulipristal）治疗子宫肌瘤。
欧洲药品管理局（European Medicines Agency, EMA）药物警戒风险评估委员会（Pharmacovigilance Risk Assessment Committee, PRAC）建议患者在药物安全性审查期间停用乌利司他治疗子宫肌瘤。审查期间欧盟范围内将暂停使用乌利司他，不可对新患者启用该治疗。[65]
2018 年，在重度肝损伤（包括导致移植的肝衰竭）得以报道后，EMA 对乌利司他治疗子宫肌瘤的获益和风险进行了审查，已采取措施将其风险最小化。[64] 然而，尽管遵循风险最小化措施，但此类病例之后又发生了另一例重度肝损伤，导致肝移植，因此 EMA 启动了新的安全性审查。
在一些国家，乌利司他被批准用于紧急避孕单剂量给药；此类限制不适用于该指征。
原始更新来源external link opens in a new window
小结
定义
病史和体格检查
诊断性检查
治疗流程
撰稿人
作者
Medical Director
Reproductive Endocrinology & Infertility
Baptist Medical Center
San Antonio Reproductive Associates
San Antonio
TX
利益声明
MM declares that he has no competing interests.
Laboratory Director
San Antonio Reproductive Associates
Odessa Reproductive Medicine Center
San Antonio
TX
利益声明
IE declares that she has no competing interests.
Dr Mitwally and Dr Elnahhas would like to gratefully acknowledge Dr Robert J. Fischer the previous contributor to this monograph. RJF declares that he has no competing interests.
同行评议者
Chairman
Department of Obstetrics and Gynecology
Naval Medical Center
Portsmouth
VA
利益声明
EM declares that he has no competing interests.
Doctor
Department of Obstetrics and Gynecology
Naval Medical Center
Portsmouth
VA
利益声明
AN declares that she has no competing interests.
Consultant Gynaecologist
University Department of Obstetrics and Gynaecology
Royal Free Hospital
London
UK
利益声明
AM declares that he has no competing interests.
内容使用需遵循免责声明